4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Macular Neovascularization Secondary to Age-Related Macular Degeneration
BIOLOGICAL: 4D-150 IVT (3E10 vg/eye)|BIOLOGICAL: EYLEAÂ® (aflibercept) Injection 2 mg (0.05mL)
Mean change from baseline in BCVA ETDRS letter score at Week 52, 52 Weeks
Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104, 104 Weeks|Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104, 104 Weeks|Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm, 104 Weeks|Mean change from baseline in CST over time through Weeks 52 and 104, 104 Weeks|Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104, 104 Weeks
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration